HeartSciences (HSCS) Receivables (2022 - 2025)

HeartSciences (HSCS) reported Receivables of $4350.0 for Q2 2025, down 70.41% quarter-over-quarter from $14700.0 in Q1 2024.

HeartSciences (HSCS) Receivables (2022 - 2025) Analysis & Trends

HeartSciences has reported Receivables for 4 years, with the latest figure at $4350.0 in Q2 2025.

For the quarter ending Q2 2025, Receivables changed N/A year-over-year to $4350.0; the trailing twelve-month figure through Apr 2025 stood at $4350.0 (changed N/A YoY), and the FY2025 full-year result was $4350.0, changed N/A from the prior year.
Receivables for Q2 2025 stood at $4350.0, down from $14700.0 in the prior quarter.
The five-year high for Receivables was $14700.0 in Q1 2024, with the low at $2321.0 in Q2 2022.
Historically, Receivables has averaged $6317.8 across 4 years, with a median of $4125.0 in 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn	8.21 Bn
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn	3.57 Bn
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn	6.36 Bn
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn	3.15 Bn
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn	973.00 Mn
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	3.82 Bn
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn	1.11 Bn
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn	4.50 Bn
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn	1.09 Bn
10	HeartSciences	3.89 Mn	492,884.20	-	-

Download Data